PMID- 9563890
OWN - NLM
STAT- MEDLINE
DCOM- 19980528
LR  - 20131121
IS  - 1078-0432 (Print)
IS  - 1078-0432 (Linking)
VI  - 4
IP  - 4
DP  - 1998 Apr
TI  - Idiotypic protein-pulsed adherent peripheral blood mononuclear cell-derived 
      dendritic cells prime immune system in multiple myeloma.
PG  - 957-62
AB  - Adherent peripheral blood mononuclear cell-derived dendritic cells pulsed with 
      autologous idiotypic protein (Id) were given to a patient with advanced-stage 
      refractory myeloma. Potentially beneficial antimyeloma Id-specific immune 
      responses were produced, characterized by MHC-dependent T-cell-proliferative 
      responses with cytokine release and the production of anti-Id antibodies. A 
      T-cell line generated after vaccination was also able to lyse autologous 
      Id-pulsed targets and recognize fresh autologous myeloma cells. The immune 
      responses were associated with a transient minor fall in the serum Id level and 
      were not ablated by high-dose myeloablative chemotherapy. This report therefore 
      demonstrates the clinical use of adherent peripheral blood mononuclear 
      cell-derived dendritic cells for vaccination in cancer and the persistence of 
      immune responses after high-dose chemotherapy. Such a therapeutic approach may be 
      useful in reducing the relapse rate in patients who have minimal residual disease 
      after chemotherapy.
FAU - Wen, Y J
AU  - Wen YJ
AD  - Department of Haematology, University of Wales College of Medicine, Heath Park, 
      Cardiff, United Kingdom.
FAU - Ling, M
AU  - Ling M
FAU - Bailey-Wood, R
AU  - Bailey-Wood R
FAU - Lim, S H
AU  - Lim SH
LA  - eng
PT  - Case Reports
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Clin Cancer Res
JT  - Clinical cancer research : an official journal of the American Association for 
      Cancer Research
JID - 9502500
RN  - 0 (Antibodies, Anti-Idiotypic)
RN  - 0 (Antibodies, Neoplasm)
RN  - 0 (Antineoplastic Agents, Alkylating)
RN  - Q41OR9510P (Melphalan)
SB  - IM
MH  - Adult
MH  - Antibodies, Anti-Idiotypic/*blood
MH  - Antibodies, Neoplasm/blood
MH  - Antineoplastic Agents, Alkylating/pharmacology/therapeutic use
MH  - Dendritic Cells/*immunology
MH  - Humans
MH  - Immunotherapy/methods
MH  - Leukocytes, Mononuclear/*immunology
MH  - Male
MH  - Melphalan/pharmacology/therapeutic use
MH  - Multiple Myeloma/drug therapy/*immunology
MH  - Vaccination
EDAT- 1998/05/14 00:00
MHDA- 1998/05/14 00:01
CRDT- 1998/05/14 00:00
PHST- 1998/05/14 00:00 [pubmed]
PHST- 1998/05/14 00:01 [medline]
PHST- 1998/05/14 00:00 [entrez]
PST - ppublish
SO  - Clin Cancer Res. 1998 Apr;4(4):957-62.